The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

This disclosure relates to synthetic oligosaccharide subunits of the Pseudomonas exosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a Pseudomonas aeruginosa Psl oligosaccharide is provided, comprising the trisaccharide of formula I.

An immunogenic glycan compound has a poly--1,4-ManNAc repeating-unit structure variably modified with 6-linked phosphoethanolamine and 6-linked phosphoglycerol.

The present disclosure relates to glycan-based biomarkers for the diagnosis or prognosis of brain damage, such as traumatic brain injury (TBI).

The present disclosure provides a method for detecting cholangiocarcinoma cells. The capture rate of the cholangiocarcinoma cells of the present disclosure is higher than 70%, and a plurality of octasaccharides with high affinity and specificity can be modified on the surface of magnetic beads to capture and analyze cholangiocarcinoma cells under test, wherein the cholangiocarcinoma cells can be circulating tumor cells in cholangiocarcinoma.

A dendritic cell immune receptor activator, comprising a compound having a sugar chain as an active ingredient, the sugar chain having a basic structure represented by the following formula: ##STR00001## wherein, in the formula, a sialic acid does not exist at two non-reducing terminals, and each of x and y independently represents 3 or 4.

The present disclosure relates to glycan-based biomarkers for the diagnosis or prognosis of brain damage, such as traumatic brain injury (TBI).

Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.

The present disclosure relates to methods of using plasma and serum (P/S) glycomics based on glycan linkage analysis that captures unique glycan features such as 2-6 sialylation, 1-6 branching, and core fucosylation as single analytical signals to evaluate the behavior of P/S glycans in all stages of lung cancer and across various stages of bladder, prostate, ovarian, and pancreatic cancer.